Topical Glycopyrrolate for Facial Sweating: What the Small Trials Measured

If sweat runs from your forehead during a meeting, a treatment that reduces that flow may help. Topical glycopyrrolate has been studied for facial hyperhidrosis, the medical term for excessive facial sweating. The strongest details come from small studies, and the treatment area matters.

The placebo comparison used two halves of the forehead

A trial published in 2015 enrolled 39 patients. Each used 2% topical glycopyrrolate on one half of the forehead and placebo on the other, once daily for nine consecutive days. Investigators weighed sweat and assessed the Hyperhidrosis Disease Severity Scale.¹

The published abstract reports these reductions in forehead sweat-production rate relative to the placebo-treated side:¹

Assessment	Reported reduction
90 minutes after the first application	25.16%
24 hours after the first application	29.63%
Day 10, after repeated applications	36.68%

The sweat measurements favored treatment significantly. The severity-scale difference did not reach significance. One participant reported a transient headache; no serious adverse events were reported during the study.¹

Measured sweat and interference with daily life are separate outcomes. A percentage reduction in weighed forehead sweat cannot tell you how many meetings a person could finish without dabbing, or whether sweat elsewhere on the scalp improved.

The roughly ten-day observation period also cannot establish long-term benefit or safety.

An earlier study suggests the effect wears off

The published summary of a 2008 study² describes 25 patients, again with 2% glycopyrrolate on one half of the forehead and placebo on the other. Sweat production favored the treated side, and 24 of 25 participants were partially or fully satisfied. Sweating returned within two days for most participants; one remained stable for up to four days.²

That is useful for setting expectations about duration. A favorable response after application is not a lasting change in the condition. Satisfaction in a small study also does not predict that every patient will prefer the treatment.

What about comparing it with injections?

A 2022 pilot randomly divided 24 patients between botulinum toxin A injections and 2% glycopyrrolate gel. Its abstract reports complete response in 75% of each group. The injection effect lasted longer, up to six months; the topical treatment had faster onset and shorter action.³

Twelve people per group is a small basis for choosing between treatments. Equal response percentages in a pilot do not establish that the treatments are equivalent. The abstract also cannot supply the detailed application and follow-up instructions needed to prescribe its gel.

Ask how the options differ in duration, repeat treatment, expense and side effects for the exact area you want treated.

The underarm cloth has different directions

The International Hyperhidrosis Society⁴ describes topical glycopyrrolate for head or face sweating as off-label use. It advises assessment for another medical condition or a medicine-related cause before treating sweating as primary hyperhidrosis.⁴

In the United States, Qbrexza is a prescription cloth containing 2.4% glycopyrronium. Its current label specifies underarm use only, not other body areas. It warns that transfer to the eyes can temporarily enlarge the pupils and blur vision, and instructs immediate handwashing with soap and water after application and disposal.⁵

A study of 2% glycopyrrolate on the forehead does not make that cloth a facial treatment. A clinician considering facial use needs to select the preparation and give its own application boundaries. Do not improvise by cutting or moving an underarm cloth onto your forehead.

The Qbrexza label also addresses urinary retention and heat illness from reduced sweating. These are reasons to review health history and other medicines with a prescriber, even for a product applied to skin.⁵

Define the result you want reviewed

Before the appointment, note whether the disruptive sweating comes from the forehead, scalp or several areas, how long it lasts and what you are doing when it begins. Our face and scalp sweating consultation guide helps organize that discussion.

If treatment is proposed, ask where it can be applied, which areas must be avoided, how to prevent eye transfer, when to stop and whom to contact if a problem occurs. Agree on a practical measure of benefit, such as needing fewer pauses to wipe your forehead during a work shift.

Chapter 10’s “Face, Scalp, and the Warm Room” section in Arms Up explains the limited research for this area and how the Fresh Log can document triggers. Take that pattern into the treatment discussion alongside the small-trial results.